EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access

Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001

Lori J Wirth iD, Marcia S Brose iD, Vivek Subbiah iD, Francis Worden, Ben Solomon iD, Bruce Robinson, Julien Hadoux iD, Pascale Tomasini, Daniela Weiler iD, Barbara Deschler-Baier, Daniel S W Tan iD, Patricia Maeda iD und 5 weitere

Journal of Clinical Oncology · 20.09.2024 · 42 (27) · 3187-3195

DOI: 10.1200/jco.23.02503 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.09.2024. Verfasst von Lori J Wirth und 16 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Thyroid Neoplasms, Pyrazoles, Pyridines. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. LIBRETTO-001 is a registrational phase I/II, single-arm, open-label study of selpercatinib in patients with RET (REarranged during Transfection)-activated cancers (ClinicalTrials.gov identifier: NCT03157128 ). We present long-term safety and efficacy from LIBRETTO-001 in patients with RET-mutant medullary thyroid cancer (MTC; n = 324) and RET fusion-positive thyroid cancer encompassing different histological subtypes (TC; n = 66). At the data cutoff of January 2023, the objective response rate was 82.5% among patients with cabozantinib/vandetanib-naïve MTC and 95.8% among patients with treatment-naïve TC. At a median follow-up time of 42.4 and 44.0 months in patients with cabozantinib/vandetanib-naïve and pretreated MTC, the median progression-free survival (PFS) was not reached and 41.4 months, respectively. At a median follow-up time of 24.9 and 30.4 months in patients with treatment-naïve and pretreated TC, the median PFS was not reached and 27.4 months, respectively. Three-year PFS rates were 75.2% and 87.3% among patients with cabozantinib/vandetanib-naïve MTC and treatment-naïve TC, respectively. Median PFS was similar to median duration of response for each patient group. The safety profile of selpercatinib was consistent with previous reports. With an additional follow-up of 37 months and 228 more patients from the last disclosure, selpercatinib continued to provide durable and robust responses in treatment-naïve and previously treated patients with RET-mutant MTC and RET fusion-positive TC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-retThyroid NeoplasmsPyrazolesPyridinesHumansMaleMiddle AgedFemaleAdultAgedCarcinoma, NeuroendocrineYoung AdultProtein Kinase InhibitorsAged, 80 and overProgression-Free SurvivalMutationAnilides

Substanzen

Proto-Oncogene Proteins c-retselpercatinibRET protein, humanPyrazolesPyridinesProtein Kinase InhibitorscabozantinibAnilides

Autor:innen und Institutionen

  • Massachusetts General Hospital, Boston, MA.
  • University of Pennsylvania, Philadelphia, PA.
  • University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sarah Cannon Research Institute, Nashville, TN.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
  • Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

ORCID-Profile: Lori J Wirth, Marcia S Brose, Vivek Subbiah, Ben Solomon, Julien Hadoux, Daniela Weiler, Daniel S W Tan, Patricia Maeda, Ravinder Singh, Alexander Drilon, Philippe A Cassier

Förderung

  • NCI NIH HHS

Zitieren

APA

Wirth, L. J., Brose, M. S., Subbiah, V., Worden, F., Solomon, B., Robinson, B., Hadoux, J., Tomasini, P., Weiler, D., Deschler-Baier, B., Tan, D. S. W., Maeda, P., Lin, Y., Singh, R., Bayt, T., Drilon, A., & Cassier, P. A. (2024). Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. Journal of Clinical Oncology, 42(27), 3187-3195. https://doi.org/10.1200/jco.23.02503

Vancouver

Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, et al. Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. Journal of Clinical Oncology. 2024;42(27):3187-3195. doi:10.1200/jco.23.02503

BibTeX
@article{Wirth2024,
  author = {Wirth, Lori J and Brose, Marcia S and Subbiah, Vivek and Worden, Francis and Solomon, Ben and Robinson, Bruce and Hadoux, Julien and Tomasini, Pascale and Weiler, Daniela and Deschler-Baier, Barbara and Tan, Daniel S W and Maeda, Patricia and Lin, Yan and Singh, Ravinder and Bayt, Theresa and Drilon, Alexander and Cassier, Philippe A},
  title = {Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {27},
  pages = {3187--3195},
  doi = {10.1200/jco.23.02503}
}
Kostenlos starten →